AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16646877 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Music-making (RMM) protocol
Number of subjects: 75
Study 10667623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral support (cheek and jaw support)
Number of subjects: 20
Study 10667623 — intervention group
Group type: COMPARATOR
Intervention: No oral support (control group)
Number of subjects: 20
Study 9049690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen administered during the luteal phase of the menstrual cycle
Number of subjects: 35
Study 9049690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tamoxifen treatment)
Number of subjects: 35
Study 8447209 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 1.8 mg.kg‐1.h‐1
Number of subjects: 40
Study 8447209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3663580 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (728 mg)
Number of subjects: 78
Study 3663580 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study 3663580 — intervention group
Group type: COMPARATOR
Intervention: alpha-tocopherol or placebo
Number of subjects: 78
Study 28324920 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM 260 mg/m2 plus carboplatin
Number of subjects: 131
Study 28324920 — intervention group
Group type: COMPARATOR
Intervention: Genexol 175 mg/m2 plus carboplatin
Number of subjects: 131
Study 28404108 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of treatment with ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin dosed twice daily
Number of subjects: 120
Study 28404108 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of treatment with ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin dosed twice daily
Number of subjects: 120
Study 28404108 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of treatment
Number of subjects: 120
Study 28404108 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of treatment
Number of subjects: 120
Study 25245352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Adolescents (DBT-A)
Number of subjects: 77
Study 25245352 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 77
Study 22152121 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Motivational Intervention (FMI)
Number of subjects: 75
Study 22152121 — intervention group
Group type: COMPARATOR
Intervention: Routine Family Support (RFS)
Number of subjects: 75
Study 21107104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 130
Study 21107104 — intervention group
Group type: COMPARATOR
Intervention: Standard management (STD)
Number of subjects: 130
Study 21107104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ANH and STD)
Number of subjects: 130
Study 18245406 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% oral sucrose and pacifier
Number of subjects: 100
Study 18245406 — intervention group
Group type: COMPARATOR
Intervention: Sterile water control solution
Number of subjects: 100
Study 15789278 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp30)
Number of subjects: 12
Study 15789278 — intervention group
Group type: COMPARATOR
Intervention: Biphasic human insulin (BHI30)
Number of subjects: 12
Study 12887149 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing with a dental explorer on one side of the lesion
Number of subjects: 10
Study 12887149 — intervention group
Group type: COMPARATOR
Intervention: Non-probed side of the lesion
Number of subjects: 10
Study 10355516 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (oral, 300 mg/day for 3 weeks starting 1 week before TAE)
Number of subjects: 73
Study 10355516 — intervention group
Group type: COMPARATOR
Intervention: Non-rebamipide group
Number of subjects: 73
Study 7794594 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment with ambulatory and domiciliary care
Number of subjects: 70
Study 7794594 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 70
Study 2200821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 25 micrograms b.i.d.
Number of subjects: 423
Study 2200821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms b.i.d.
Number of subjects: 423
Study 2200821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 400 micrograms b.i.d.
Number of subjects: 423
Study 2200821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 7023307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol 750 mg/d
Number of subjects: 916
Study 7023307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol 375 mg/d
Number of subjects: 916
Study 7023307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study 31683467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg for 15 min before incision, followed by 0.3‐0.5 μg/(kg·h) till the end of the operation)
Number of subjects: 60
Study 31683467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 31683467 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 29595640 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 90
Study 29595640 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 90
Study 29595640 — intervention group
Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 90
Study 27661399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) mixed with orange juice
Number of subjects: 30
Study 27661399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) mixed with yogurt
Number of subjects: 30
Study 24374288 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-type exercise training with protein supplementation (2×15 g daily)
Number of subjects: 127
Study 24374288 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-type exercise training without protein supplementation
Number of subjects: 127
Study 24374288 — intervention group
Group type: COMPARATOR
Intervention: No exercise program (Control)
Number of subjects: 127
Study 22616830 — intervention group
Group type: EXPERIMENTAL
Intervention: DrotAA (24 μg/kg/hour) for 96 hours
Number of subjects: 1697
Study 22616830 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 96 hours
Number of subjects: 1697
Study 22616830 — intervention group
Group type: EXPERIMENTAL
Intervention: DrotAA (24 μg/kg/hour) for 96 hours in patients with severe protein C deficiency
Number of subjects: 1697
Study 22616830 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 96 hours in patients with severe protein C deficiency
Number of subjects: 1697
Study 20805258 — intervention group
Group type: EXPERIMENTAL
Intervention: Glulisine
Number of subjects: 180
Study 20805258 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 180
Study 17634053 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Optimization Program (TOP) tool
Number of subjects: 2573
Study 17634053 — intervention group
Group type: COMPARATOR
Intervention: Usual ED management (non-TOP)
Number of subjects: 2573
Study 17634053 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP tool (video and brochure)
Number of subjects: 2573
Study 17634053 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP tool usage by physicians
Number of subjects: 2573
Study 16372518 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (20 mg metal zinc)
Number of subjects: 12
Study 16372518 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide (17.4 mg metal zinc)
Number of subjects: 12
Study 11942448 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultations
Number of subjects: 388
Study 11942448 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 388
Study 9657654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1600 microg daily for 2 months
Number of subjects: 30
Study 9657654 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by budesonide
Number of subjects: 30
Study 7814824 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliprodil 30 mg
Number of subjects: 11
Study 7814824 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 15 mg (positive control)
Number of subjects: 11
Study 7814824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2517696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral content in the distal forearm by single photon (125I) absorptiometry
Number of subjects: 118
Study 2517696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral content and bone mineral density of the lumbar spine measured by dual photon (153Gd) absorptiometry
Number of subjects: 118
Study 2517696 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body bone mineral and total body bone density measured by dual photon (153Gd) absorptiometry
Number of subjects: 118
Study 2517696 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm scanner
Number of subjects: 118
Study 2517696 — intervention group
Group type: COMPARATOR
Intervention: Spine scanner
Number of subjects: 118
Study 30229939 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (7 DU)
Number of subjects: 219
Study 30229939 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (12 DU)
Number of subjects: 219
Study 30229939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 27045369 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weightbearing (weightbearing and ROM at 2 weeks)
Number of subjects: 110
Study 27045369 — intervention group
Group type: COMPARATOR
Intervention: Late weightbearing (nonweightbearing and cast immobilization for 6 weeks)
Number of subjects: 110
Study 24961880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose α-tocopherol supplementation
Number of subjects: 1746
Study 24961880 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm (control)
Number of subjects: 1746
Study 24961880 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine supplementation
Number of subjects: 1746
Study 24961880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade prostate cancer (Gleason grade 7-10) with α-tocopherol
Number of subjects: 1746
Study 24961880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade prostate cancer (Gleason grade 7-10) with selenomethionine
Number of subjects: 1746
Study 22770920 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200mg oral gabapentin
Number of subjects: 64
Study 22770920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20109575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue 1 mg/kg
Number of subjects: 15
Study 20109575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue 3 mg/kg
Number of subjects: 15
Study 20109575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue 7 mg/kg
Number of subjects: 15
Study 20109575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (all doses)
Number of subjects: 15
Study 20109575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (high doses)
Number of subjects: 15
Study 18664347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanreqing injection (20 ml, once daily for 10 days)
Number of subjects: 90
Study 18664347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride injection (15 mg, twice daily for 10 days)
Number of subjects: 90
Study 18664347 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 90
Study 18664347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanreqing injection
Number of subjects: 90
Study 18664347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride injection
Number of subjects: 90
Study 15856479 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB) induction and daily mycophenolate mofetil with steroids
Number of subjects: 51
Study 15856479 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus-based triple therapy
Number of subjects: 51
Study 12008989 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week behavior modification intervention emphasizing increasing diet nutrient-density
Number of subjects: 31
Study 9371155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel (Cerestat)
Number of subjects: 600
Study 9371155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 1827074 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + 30 micrograms ethinyl estradiol
Number of subjects: 26
Study 1827074 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + 50 micrograms ethinyl estradiol
Number of subjects: 26
Study 1827074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 2 mg + 35 micrograms ethinyl estradiol
Number of subjects: 26
Study 1827074 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 normal women, not treated)
Number of subjects: 26
Study 1827074 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 26
Study 6960390 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 0.5 mg three times daily and 1 mg at night
Number of subjects: 28
Study 6960390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6960390 — intervention group
Group type: COMPARATOR
Intervention: PGE2 and Placebo
Number of subjects: 28
Study 31898644 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe group (computer‐aided detection system)
Number of subjects: 1026
Study 31898644 — intervention group
Group type: COMPARATOR
Intervention: Control group (without CADe system)
Number of subjects: 1026
Study 30589759 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Viewing Training (EVT)
Number of subjects: 76
Study 30589759 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study 28117385 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 872
Study 25242512 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) reconstruction
Number of subjects: 78
Study 25242512 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle (SB) reconstruction
Number of subjects: 78
Study 25066556 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided angioplasty
Number of subjects: 250
Study 25066556 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty under fluoroscopy alone
Number of subjects: 250
Study 22735650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical compression
Number of subjects: 212
Study 22735650 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 212
Study 19463506 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/day
Number of subjects: 42
Study 19463506 — intervention group
Group type: COMPARATOR
Intervention: ramipril 5 mg/day
Number of subjects: 42
Study 17763588 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam dissolved in glucose solution (n = 50)
Number of subjects: 100
Study 17763588 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution only with communication technique (n = 50)
Number of subjects: 100
Study 15530676 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine (Varilrix)
Number of subjects: 42
Study 15530676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11354528 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of melatonin
Number of subjects: 12
Study 11354528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9602585 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 10 mg i.m. (group MX)
Number of subjects: 62
Study 9602585 — intervention group
Group type: COMPARATOR
Intervention: 6% hetastarch 500 ml and crystalloid 500 ml (group HS)
Number of subjects: 62
Study 7472698 — intervention group
Group type: EXPERIMENTAL
Intervention: LFG + propranolol
Number of subjects: 312
Study 7472698 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 312
Study 7472698 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 312
Study 7472698 — intervention group
Group type: COMPARATOR
Intervention: LFG + placebo
Number of subjects: 312
Study 7472698 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 312
Study 7472698 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and placebo
Number of subjects: 312
Study 2275207 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumalon-injections
Number of subjects: 14
Study 2275207 — intervention group
Group type: COMPARATOR
Intervention: Galvanic bath alone
Number of subjects: 14
Study 2275207 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumalon-group
Number of subjects: 14
Study 2275207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 2275207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scanning
Number of subjects: 14
Study 365920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 43
Study 365920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30821630 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic‐focused Psychodynamic therapy (PFPP)
Number of subjects: 161
Study 30821630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 161
Study 30821630 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 161
Study 29777234 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy products (≈1500 mg calcium/day)
Number of subjects: 80
Study 29777234 — intervention group
Group type: COMPARATOR
Intervention: Low dairy products (≤600 mg calcium/day)
Number of subjects: 80
Study 29777234 — intervention group
Group type: EXPERIMENTAL
Intervention: Above 30 g fiber/10MJ
Number of subjects: 80
Study 29777234 — intervention group
Group type: COMPARATOR
Intervention: Below 30 g fiber/10MJ
Number of subjects: 80
Study 29777234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake
Number of subjects: 80
Study 28127938 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed naloxegol 25-mg tablets (suspended in water) administered orally
Number of subjects: 0
Study 28127938 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed naloxegol 25-mg tablets (suspended in water) administered by nasogastric tube
Number of subjects: 0
Study 28127938 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol solution
Number of subjects: 0
Study 28127938 — intervention group
Group type: COMPARATOR
Intervention: Commercially available 25-mg tablet formulation
Number of subjects: 0
Study 24549209 — intervention group
Group type: EXPERIMENTAL
Intervention: New method of suspension
Number of subjects: 24
Study 24549209 — intervention group
Group type: COMPARATOR
Intervention: Conventional suction suspension
Number of subjects: 24
Study 24549209 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger prosthesis (both types)
Number of subjects: 24
Study 23764087 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy foods and beverages observed on campuses
Number of subjects: 4033
Study 23764087 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy foods and beverages
Number of subjects: 4033
Study 21775837 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, self-obtained vaginal swabs (swab collection kits mailed to home)
Number of subjects: 1292
Study 21775837 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based rescreening (made clinic appointments)
Number of subjects: 1292
Study 19411357 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular evidence-based treatment protocol
Number of subjects: 59
Study 19411357 — intervention group
Group type: COMPARATOR
Intervention: Standard evidence-based treatment protocol
Number of subjects: 59
Study 18005908 — intervention group
Group type: COMPARATOR
Intervention: Blinded placebo
Number of subjects: 720
Study 18005908 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded echinacea
Number of subjects: 720
Study 18005908 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded open-label echinacea
Number of subjects: 720
Study 18005908 — intervention group
Group type: COMPARATOR
Intervention: No doctor-patient interaction
Number of subjects: 720
Study 18005908 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doctor-patient interaction
Number of subjects: 720
Study 18005908 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced doctor-patient interaction
Number of subjects: 720
Study 15369126 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11844172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound follow-up
Number of subjects: 97
Study 11844172 — intervention group
Group type: COMPARATOR
Intervention: Dilatation and curettage
Number of subjects: 97
Study 9744490 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 320 mg
Number of subjects: 9
Study 9744490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9744490 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 160 mg
Number of subjects: 9
Study 9744490 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg
Number of subjects: 9
Study 10461420 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 30
Study 10461420 — intervention group
Group type: COMPARATOR
Intervention: Sulbactam-cefoperazone plus amikacin
Number of subjects: 30
Study 2695956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg)
Number of subjects: 18
Study 2695956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg)
Number of subjects: 18
Study 2695956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 137693 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (135 mg daily)
Number of subjects: 0
Study 137693 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate plus vitamin A (300,000 IU daily)
Number of subjects: 0